NCT04337138 2021-08-09
A Study Of Treatment Patterns And Clinical Outcomes In Patients Diagnosed With Acute Myeloid Leukemia Who Received Mylotarg in the Real-World
Pfizer
Completed
Clinical Trials
9 trialsNCT00037596 2013-02-13
Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid Leukemia
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 2 Completed
NCT00003673 2012-08-22
CMA-676 in Treating Older Patients With Acute Myeloid Leukemia in First Relapse
Pfizer
Phase 2 Completed
NCT00037583 2009-08-21
Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 2 Completed
NCT00962767 2009-08-20
Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 3 Completed
NCT00304447 2009-07-29
Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 4 Completed
NCT00233909 2008-04-01
A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia
Kanisa Pharmaceuticals
Phase 1/2 Completed
NCT00161668 2007-03-15
Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care
Wyeth is now a wholly owned subsidiary of Pfizer
Completed
NCT00044733 2006-05-18
Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 2 Completed